A Phase 1 Open-Label Single-Dose Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Trial Profile

A Phase 1 Open-Label Single-Dose Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs Enasidenib (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 26 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top